Regulation of NF-kappaB by Small Ubiquitin-Like Modifiers
小泛素样修饰剂对 NF-kappaB 的调节
基本信息
- 批准号:8098970
- 负责人:
- 金额:$ 28.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-08-01 至 2014-07-31
- 项目状态:已结题
- 来源:
- 关键词:Antineoplastic AgentsAutoimmunityB Cell ProliferationB-LymphocytesBreast Cancer CellCell DeathCell Death Signaling ProcessCell ProliferationCell Signaling ProcessCell SurvivalCell physiologyComplexDataDefectDevelopmentDiseaseExperimental ModelsFamilyGerm-Line MutationGoalsHumanImmuneImmunityInflammatoryKnowledgeLinkLiteratureMalignant NeoplasmsMalignant neoplasm of prostateMolecularMusNF-kappa BNormal CellPathologic ProcessesPathway interactionsPeptide HydrolasesPhysiological ProcessesPlayPost-Translational Protein ProcessingProcessReagentRegulationRegulatory PathwayResearchResearch PersonnelRoleSignal PathwaySignal TransductionSignaling ProteinSiteStressSystemTestingUbiquitincancer celldrug developmentmalignant breast neoplasmmutantnoveloverexpressionpreventpublic health relevanceresponsetooltranscription factortumor
项目摘要
DESCRIPTION (provided by applicant): The NF-?B/Rel family of transcription factors contributes to critical cellular processes, including immune, inflammatory and cell survival responses. As such, NF-?B is implicated in immunity-related diseases, such as autoimmunity, as well as multiple types of human malignancies. Understanding mechanisms of NF-?B regulation will not only expand our knowledge of basic cell signaling processes but also provide potential avenues to prevent and/or treat these human disorders. While a large body of literature over the last two decades describes the critical roles of ubiquitin in regulating NF-?B functions, very little is known about regulation of NF-?B signaling by SUMO (small ubiquitin-like modifier), another posttranslational modifier. The long-term goal of this project is to greatly expand our understanding of the mechanisms of NF-?B and SUMO regulation in specific physiological and pathological processes. We have recently uncovered a novel signaling role for SUMOylation of NEMO (NF-?B essential modulator) in NF-?B signaling. Our preliminary data indicate that there exist significant, novel crosstalk mechanisms between the SUMO and NF-?B pathways. Thus, in this proposal, we will test the hypothesis that crosstalk between SUMO and NF-?B signaling systems plays critical roles in regulating certain physiological and pathological processes. This research is expected to considerably expand our knowledge of the molecular links between SUMO and NF-?B pathways and their roles in specific physiological and pathological processes. This research will also generate novel reagents and tools to allow other researchers to investigate SUMO and NF-?B signaling systems in similar and different experimental models. Finally, it may also identify rational targets for drug development against human disorders, such as autoimmunity and specific types of malignancies.
PUBLIC HEALTH RELEVANCE: The regulation of cancer cell death is a complex process involving many different molecular pathways. This research seeks to understand the relationships between protein modification by SUMO (Small Ubiquitin-like Modifier) and NF-?B signaling, one of the major cell death-regulatory pathways. This study will significantly expand our understanding of the regulatory mechanisms for normal and cancer cell death signaling, and may also provide rationale targets for the development of new anticancer drugs.
描述(由申请人提供):NF-?B/Rel家族转录因子参与关键的细胞过程,包括免疫、炎症和细胞生存反应。因此,NF-?B参与免疫相关疾病,如自身免疫,以及多种类型的人类恶性肿瘤。了解NF-?B调节不仅将扩大我们对基本细胞信号传导过程的认识,而且还将为预防和/或治疗这些人类疾病提供潜在的途径。在过去的二十年里,大量的文献描述了泛素在调节NF-?B的功能,我们对NF-?B信号通过另一种翻译后修饰剂SUMO(小泛素样修饰剂)传递。该项目的长期目标是大大扩展我们对NF-?B和SUMO在特定生理病理过程中的调控。我们最近发现了NEMO (NF-?) summoylation的一个新的信号作用。B本质调制器)在NF-?B信号。我们的初步数据表明,在SUMO和NF-?之间存在着重要的、新的串扰机制。B通路。因此,在本提案中,我们将检验相扑和NF-?B信号系统在调节某些生理和病理过程中起关键作用。这项研究有望大大扩展我们对SUMO和NF-?B通路及其在特定生理和病理过程中的作用。这项研究还将产生新的试剂和工具,使其他研究人员能够研究SUMO和NF-?相似和不同实验模型中的B信号系统。最后,它还可以确定针对人类疾病(如自身免疫和特定类型的恶性肿瘤)的药物开发的合理靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHIGEKI MIYAMOTO其他文献
SHIGEKI MIYAMOTO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHIGEKI MIYAMOTO', 18)}}的其他基金
Impact of Host NF-kB Signaling in Radiation Therapy
宿主 NF-kB 信号传导在放射治疗中的影响
- 批准号:
10434953 - 财政年份:2021
- 资助金额:
$ 28.67万 - 项目类别:
Impact of Host NF-kB Signaling in Radiation Therapy
宿主 NF-kB 信号传导在放射治疗中的影响
- 批准号:
10297956 - 财政年份:2021
- 资助金额:
$ 28.67万 - 项目类别:
Impact of Host NF-kB Signaling in Radiation Therapy
宿主 NF-kB 信号传导在放射治疗中的影响
- 批准号:
10665545 - 财政年份:2021
- 资助金额:
$ 28.67万 - 项目类别:
New Multi-Drug Resistance Mechanism in Multiple Myeloma
多发性骨髓瘤多重耐药新机制
- 批准号:
10439626 - 财政年份:2020
- 资助金额:
$ 28.67万 - 项目类别:
New Multi-Drug Resistance Mechanism in Multiple Myeloma
多发性骨髓瘤多重耐药新机制
- 批准号:
10626002 - 财政年份:2020
- 资助金额:
$ 28.67万 - 项目类别:
New Multi-Drug Resistance Mechanism in Multiple Myeloma
多发性骨髓瘤多重耐药新机制
- 批准号:
10029257 - 财政年份:2020
- 资助金额:
$ 28.67万 - 项目类别:
New Multi-Drug Resistance Mechanism in Multiple Myeloma
多发性骨髓瘤多重耐药新机制
- 批准号:
10187534 - 财政年份:2020
- 资助金额:
$ 28.67万 - 项目类别:
Regulation of NEMO modifications in radiation-induced NF-kB signaling
辐射诱导的 NF-kB 信号传导中 NEMO 修饰的调节
- 批准号:
8656285 - 财政年份:2013
- 资助金额:
$ 28.67万 - 项目类别:
Regulation of NF-kappaB by Small Ubiquitin-Like Modifiers
小泛素样修饰剂对 NF-kappaB 的调节
- 批准号:
7986606 - 财政年份:2010
- 资助金额:
$ 28.67万 - 项目类别:
Regulation of NF-kappaB by Small Ubiquitin-Like Modifiers
小泛素样修饰剂对 NF-kappaB 的调节
- 批准号:
8505491 - 财政年份:2010
- 资助金额:
$ 28.67万 - 项目类别:
相似海外基金
Thymus antibody-secreting cells: major players in autoimmunity.
胸腺抗体分泌细胞:自身免疫的主要参与者。
- 批准号:
502578 - 财政年份:2024
- 资助金额:
$ 28.67万 - 项目类别:
B cell development, autoimmunity and immune regulation
B 细胞发育、自身免疫和免疫调节
- 批准号:
MR/Y033701/1 - 财政年份:2024
- 资助金额:
$ 28.67万 - 项目类别:
Research Grant
Applying advanced understanding of CTLA-4 function to optimise therapies for autoimmunity
应用对 CTLA-4 功能的深入理解来优化自身免疫疗法
- 批准号:
MR/Y001273/1 - 财政年份:2024
- 资助金额:
$ 28.67万 - 项目类别:
Research Grant
MUC16 (CA125) mutations promote fibrosis and autoimmunity in systemic sclerosis
MUC16 (CA125) 突变促进系统性硬化症的纤维化和自身免疫
- 批准号:
478933 - 财政年份:2023
- 资助金额:
$ 28.67万 - 项目类别:
Operating Grants
Development of serologic test for early risk stratification of islet autoimmunity in genetically predisposed T1D individuals
开发用于遗传易感性 T1D 个体胰岛自身免疫早期风险分层的血清学检测
- 批准号:
10760885 - 财政年份:2023
- 资助金额:
$ 28.67万 - 项目类别:
Mechanisms of New-Onset Autoimmunity/Longitudinal Immune Systems Analysis (MONA-LISA)
新发自身免疫/纵向免疫系统分析(MONA-LISA)的机制
- 批准号:
10655219 - 财政年份:2023
- 资助金额:
$ 28.67万 - 项目类别:
Autoimmunity-Associated B Cells in Lupus Nephritis
狼疮性肾炎中自身免疫相关的 B 细胞
- 批准号:
10582053 - 财政年份:2023
- 资助金额:
$ 28.67万 - 项目类别:
Heparan sulfate as a platform to boost regulatory T cell suppression of autoimmunity
硫酸乙酰肝素作为增强调节性 T 细胞抑制自身免疫的平台
- 批准号:
490663 - 财政年份:2023
- 资助金额:
$ 28.67万 - 项目类别:
Operating Grants
The interplay of sex hormones and chromosomes dictates pathogenicity in progressive CNS autoimmunity.
性激素和染色体的相互作用决定了进行性中枢神经系统自身免疫的致病性。
- 批准号:
488982 - 财政年份:2023
- 资助金额:
$ 28.67万 - 项目类别:
Operating Grants
Understanding autoimmunity: Why do B cells sometimes attack our tissues instead of protecting us from infections?
了解自身免疫:为什么 B 细胞有时会攻击我们的组织而不是保护我们免受感染?
- 批准号:
2889164 - 财政年份:2023
- 资助金额:
$ 28.67万 - 项目类别:
Studentship